Streetbeat News

Regulatory

NAYA

NAYA Biosciences has announced the initiation of a Phase 1/2a clinical trial for its GPC3-targeted NK Engager bispecific antibody, NY-303, in patients with hepatocellular carcinoma. The trial has received regulatory approval in Israel and will be conducted in up to 7 academic centers.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 1:17 pm

ABT

Abbott has initiated the TEAM-HF clinical trial, aiming to improve outcomes for patients with advanced heart failure. The trial seeks to establish new criteria to identify patients at risk for end-stage heart failure, potentially offering life-saving treatments earlier.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 1:11 pm

SGD

Safe And Green Development Corporation has regained compliance with Nasdaq's minimum bid price requirement, ensuring its continued listing on the exchange.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 1:06 pm

ETN

GS

TDG

On CNBC's 'Halftime Report Final Trades,' Eaton Corporation (ETN) was highlighted ahead of its Q3 earnings report, with expectations of increased earnings and revenue. TransDigm Group (TDG) received a price target increase from JPMorgan, while Goldman Sachs (GS) faced an $89 million fine related to Apple Card issues.

Portfolio Pulse from Avi Kapoor

October 24, 2024 | 1:05 pm

IBRX

ImmunityBio has initiated a Phase 1 clinical study of its CAR-NK cell therapy for relapsed B-Cell Non-Hodgkin Lymphoma. This marks the company's first trial of CAR-NK cellular therapy in liquid tumors and the first natural killer cell-based therapy study in Africa. Full enrollment is expected by Q1 2025.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 1:05 pm

AG

Silver prices have surged over 6%, causing potential billion-dollar losses for five US banks with large short positions. This has raised concerns about market integrity and the impact on industries reliant on stable silver prices. Increased investor interest in precious metals is noted, with significant options activity in First Majestic Silver (NYSE:AG) indicating bullish sentiment.

Portfolio Pulse from Rounak Jain

October 24, 2024 | 1:01 pm

SPY

The Federal Reserve's Hammack stated that inflation has eased significantly but has not yet reached the target. Recent months have shown improved inflation readings, with Fed policy contributing to this cooling process. Despite strong job market and growth, longer-term inflation expectations remain anchored.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 12:57 pm

DTIL

Precision BioSciences has received approval for its clinical trial application in Moldova to initiate the PBGENE-HBV study, marking the first in vivo gene editing program for chronic hepatitis B to enter global clinical trials. The company plans to host an investor event to discuss safety data and trial plans.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 12:50 pm

OMER

Omeros Corporation has received the FDA Rare Pediatric Disease Designation for its drug candidate Zaltenibart, aimed at treating C3 glomerulopathy, a rare kidney disease. This designation could potentially expedite the drug's development and approval process.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 12:46 pm

LUCY

Innovative Eyewear has received a Notice of Allowance for its utility patent application for 'Wireless Smartglasses with Quick Connect Front Frames'. This development could enhance their product offerings and market position.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 12:38 pm